Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Receives Consensus Recommendation of “Hold” from Analysts

Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) have been given a consensus recommendation of “Hold” by the five analysts that are presently covering the company, MarketBeat reports. Three research analysts have rated the stock with a hold rating and two have issued a buy rating on the company. The average 1 year target price among brokers that have issued a report on the stock in the last year is $40.75.

Several equities analysts have recently weighed in on the stock. Needham & Company LLC lowered shares of Collegium Pharmaceutical from a “buy” rating to a “hold” rating in a research report on Friday, May 10th. Piper Sandler lowered shares of Collegium Pharmaceutical from an “overweight” rating to a “neutral” rating and set a $39.00 price target on the stock. in a research report on Friday, May 10th. StockNews.com lowered shares of Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, May 1st. Finally, Jefferies Financial Group raised shares of Collegium Pharmaceutical from a “hold” rating to a “buy” rating and raised their price target for the stock from $41.00 to $44.00 in a research report on Friday, June 7th.

Insider Buying and Selling at Collegium Pharmaceutical

In other Collegium Pharmaceutical news, CFO Colleen Tupper sold 19,710 shares of the firm’s stock in a transaction dated Tuesday, May 28th. The shares were sold at an average price of $34.21, for a total value of $674,279.10. Following the transaction, the chief financial officer now directly owns 130,845 shares of the company’s stock, valued at approximately $4,476,207.45. The transaction was disclosed in a legal filing with the SEC, which is available through this link. In other news, Director Garen G. Bohlin sold 28,985 shares of the firm’s stock in a transaction that occurred on Tuesday, May 14th. The shares were sold at an average price of $32.30, for a total value of $936,215.50. Following the sale, the director now directly owns 44,775 shares in the company, valued at approximately $1,446,232.50. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CFO Colleen Tupper sold 19,710 shares of the firm’s stock in a transaction that occurred on Tuesday, May 28th. The shares were sold at an average price of $34.21, for a total transaction of $674,279.10. Following the completion of the sale, the chief financial officer now owns 130,845 shares in the company, valued at $4,476,207.45. The disclosure for this sale can be found here. Insiders have sold a total of 105,502 shares of company stock valued at $3,540,796 in the last ninety days. 3.98% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Collegium Pharmaceutical

A number of hedge funds have recently made changes to their positions in the stock. ProShare Advisors LLC boosted its stake in shares of Collegium Pharmaceutical by 3.3% in the 1st quarter. ProShare Advisors LLC now owns 8,826 shares of the specialty pharmaceutical company’s stock valued at $343,000 after purchasing an additional 281 shares in the last quarter. SummerHaven Investment Management LLC boosted its stake in shares of Collegium Pharmaceutical by 1.1% in the 4th quarter. SummerHaven Investment Management LLC now owns 34,034 shares of the specialty pharmaceutical company’s stock valued at $1,048,000 after purchasing an additional 368 shares in the last quarter. Texas Permanent School Fund Corp boosted its stake in shares of Collegium Pharmaceutical by 1.3% in the 1st quarter. Texas Permanent School Fund Corp now owns 28,541 shares of the specialty pharmaceutical company’s stock valued at $1,108,000 after purchasing an additional 369 shares in the last quarter. Illinois Municipal Retirement Fund boosted its stake in shares of Collegium Pharmaceutical by 2.1% in the 4th quarter. Illinois Municipal Retirement Fund now owns 19,879 shares of the specialty pharmaceutical company’s stock valued at $612,000 after purchasing an additional 411 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD boosted its stake in shares of Collegium Pharmaceutical by 1.9% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 29,282 shares of the specialty pharmaceutical company’s stock valued at $1,137,000 after purchasing an additional 535 shares in the last quarter.

Collegium Pharmaceutical Stock Performance

Shares of COLL opened at $32.36 on Thursday. The stock has a market capitalization of $1.06 billion, a price-to-earnings ratio of 13.48 and a beta of 0.93. The firm has a fifty day simple moving average of $33.64 and a 200 day simple moving average of $34.40. Collegium Pharmaceutical has a 12 month low of $20.83 and a 12 month high of $40.95. The company has a current ratio of 1.21, a quick ratio of 1.14 and a debt-to-equity ratio of 1.98.

Collegium Pharmaceutical (NASDAQ:COLL) last issued its quarterly earnings data on Thursday, May 9th. The specialty pharmaceutical company reported $1.32 earnings per share for the quarter, missing the consensus estimate of $1.36 by ($0.04). The company had revenue of $144.92 million during the quarter, compared to the consensus estimate of $147.04 million. Collegium Pharmaceutical had a net margin of 16.46% and a return on equity of 104.98%. Research analysts forecast that Collegium Pharmaceutical will post 5.57 EPS for the current fiscal year.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.